Last October Novo Nordisk announced that it ... An oral version of insulin would be an enormous breakthrough in treating type 1 and type 2 diabetes patients, as freedom from daily injections ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

The US Food and Drug Administration on Monday approved Hikma Pharmaceuticals’ generic version of Novo Nordisk’s diabetes ... aged 10 years or older with type 2 diabetes. Demand for the drug ...

Novo Nordisk has developed semaglutide, a drug based on GLP-1 receptor activation, which increases pancreatic insulin release ...

Novo Nordisk (NVO) announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a ...